Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > March 31, 2020
Daily News
March 31, 2020
- Keidanren Calls for Support in Drug, Vaccine Development: Emergency Proposal
March 31, 2020
- Shionogi Hooks Up with China’s Biggest Insurance Group, Eyes RWD-Based Drug Development
March 31, 2020
- Japan Pharma Industry Presses for 100 Billion Yen Emergency Package over Coronavirus, Stable Supplies
March 31, 2020
- Ono Expands I/O Collaboration with Swiss Firm Numab
March 31, 2020
- Fujifilm Wants to Launch Avigan Trial in Japan by End of This Week, Abe Talks to WHO Chief
March 31, 2020
- Japan’s 1st In Vitro Diagnostic Test Kit for Novel Coronavirus Approved: Sysmex
March 31, 2020
- Healios to Boost Its Stake in US Biotech Athersys
March 31, 2020
- Global Health Confab Issues Proposals for Regulatory Harmonization in Asia
March 31, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…